AU1317000A - Method of treating immunological disorders mediated by t-lymphocytes - Google Patents

Method of treating immunological disorders mediated by t-lymphocytes

Info

Publication number
AU1317000A
AU1317000A AU13170/00A AU1317000A AU1317000A AU 1317000 A AU1317000 A AU 1317000A AU 13170/00 A AU13170/00 A AU 13170/00A AU 1317000 A AU1317000 A AU 1317000A AU 1317000 A AU1317000 A AU 1317000A
Authority
AU
Australia
Prior art keywords
lymphocytes
disorders mediated
immunological disorders
treating immunological
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13170/00A
Inventor
David Erickson
Peter M. Grob
Ann F. Hoffman
Thomas C. Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU1317000A publication Critical patent/AU1317000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU13170/00A 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes Abandoned AU1317000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10487598P 1998-10-20 1998-10-20
US60104875 1998-10-20
PCT/US1999/024371 WO2000023060A2 (en) 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes

Publications (1)

Publication Number Publication Date
AU1317000A true AU1317000A (en) 2000-05-08

Family

ID=22302869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13170/00A Abandoned AU1317000A (en) 1998-10-20 1999-10-19 Method of treating immunological disorders mediated by t-lymphocytes

Country Status (2)

Country Link
AU (1) AU1317000A (en)
WO (1) WO2000023060A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372334T1 (en) * 2001-06-29 2007-09-15 Boehringer Ingelheim Pharma PHENYLPYRAZOLE DERIVATIVES AS VISION INHIBITORS
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050222252A1 (en) * 2004-03-31 2005-10-06 The Regents Of The University Of California Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
WO2006133257A2 (en) 2005-06-06 2006-12-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
CA2619768A1 (en) 2005-08-19 2007-02-22 The Regents Of The University Of California Use of seh inhibitors as analgesics
JP2009518442A (en) * 2005-12-05 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
CA2671837A1 (en) 2006-12-18 2008-06-26 F. Hoffmann-La Roche Ag Novel use of inhibitors of soluble epoxide hydrolase
EP2178534A4 (en) 2007-07-17 2011-03-30 Merck Sharp & Dohme Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8809552B2 (en) 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2013138118A1 (en) * 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US20160008342A1 (en) 2014-06-16 2016-01-14 The Regents Of The University Of California Methods of improving cell-based therapy
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain
EP3584236A1 (en) 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
EP4063348A1 (en) 2021-03-24 2022-09-28 Universitat de Barcelona Compounds as soluble epoxide hydrolase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2000023060A2 (en) 2000-04-27
WO2000023060A8 (en) 2001-03-01
WO2000023060A3 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
AU7085100A (en) Method for treating otic disorders
AU4880197A (en) Method for treatment of dermatological disorders
AU4977597A (en) Process for the fractionation of polyoxyalkylene block copolymers
AU1317000A (en) Method of treating immunological disorders mediated by t-lymphocytes
AU3977700A (en) Method of treating neurological disorders
AU2660099A (en) Readily absorbable phytosterols to treat hypercholesterrolemia
AU5042000A (en) Methods of treating proliferative disorders
AU2105399A (en) Method of preparing treated silica
AU1629895A (en) Method for production of pyromellitic anhydride
AU2251897A (en) Method of treating liver disorders
AU2001288792A1 (en) Method of treating neurologic disorders
AU3757300A (en) Method of treating anxiety disorders
AU5198898A (en) Method for treatment of glutamate related disorders
AU2354800A (en) Method of protein removal
AU2022597A (en) A method of treating disorders related to cytokines in mammals
AU2993997A (en) New method of forming fine circuit lines
AU1133901A (en) Method of treating metabolic disorders
AU6409499A (en) Method of treatment of cardiovascular injuries
AU1735800A (en) Method of treating seizure disorders
AU2759400A (en) Method for maintenance and selection of episomes
AU2022497A (en) A method of treating disorders related to cytokines in mammals
AU1282099A (en) Method for treatment of disorders of attention
AU4916197A (en) Method for topical treatment of nonviral epithelial disorders
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU4027097A (en) Method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase